Tabloid

(Thioguanine)

ApprovedSmall molecule

Thioguanine is used to treat certain types of leukemia (blood cancer) by slowing or stopping the growth of cancer cells in the bone marrow.[2] Tabloid is currently approved and in use across 11 indications[4].[1]

Tabloid is one of 173 small molecule programs targeting Langerhans Cell Histiocytosis. It is currently in Approved.

Indications

Total Trials

Active Trials

172

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Langerhans Cell HistiocytosisApproved

Non-Hodgkins LymphomaApproved

Acute Myeloid Leukemia by FAB ClassificationActive, not recruiting

B Acute Lymphoblastic LeukemiaActive, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaActive, not recruiting

Adult T Acute Lymphoblastic LeukemiaActive, not recruiting

T Lymphoblastic Leukemia/lymphomaNot yet recruiting

Acute Lymphoblastic LeukemiaCompleted

Lymphoblastic LymphomaRecruiting

T-Cell Acute Lymphoblastic LeukemiaWithdrawn

Langerhans Cell HistiocytosisApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Acute Myeloid Leukemia by FAB ClassificationApproved

Active, not recruiting

B Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Adult T Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

T Lymphoblastic Leukemia/lymphomaPreclinical

Not yet recruiting

Acute Lymphoblastic LeukemiaApproved

Completed

Lymphoblastic LymphomaApproved

Recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Withdrawn

Showing 10 of 11 indications

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

17 5

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 6

Vanflyta

Daiichi Sankyo

Phase 3

14 7

Tabloid

Akero Therapeutics

Approved

3 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Cellcept

Busulfex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02883049

Q2 2027

Phase 3Active, not recruiting

Acute Myeloid Leukemia

NCT02521493

Q3 2027

Phase 3Recruiting

B Acute Lymphoblastic Leukemia

NCT03150693

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03007147

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT03571321

Phase 3Active, not recruiting

B Acute Lymphoblastic Leukemia

NCT03914625

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia39 trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02883049·5,949 enrolled

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00022126·6 enrolled

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002816·120 enrolled

Show 36 more trials

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01156883·76 enrolled

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002514·1,929 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT00430118·4,559 enrolled

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005603·276 enrolled

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005585·838 enrolled

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Unknown status·SSun Yat-sen University·Phase 2·NCT02660762·100 enrolled

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02419469·1 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005596·1,076 enrolled

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005945·3,054 enrolled

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·—·Phase 3·NCT00764907·4,000 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002744·1,970 enrolled

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Completed·CChildren's Oncology Group·Phase 1·NCT00866307·104 enrolled

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01190930·9,350 enrolled

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00103285·5,377 enrolled

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00016302·100 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00343369·550 enrolled

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Unknown status·MMedical Research Council·Phase 3·NCT00003437·1,800 enrolled

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00075725·3,154 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00558519·318 enrolled

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00866749·120 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003728·1,500 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Completed·GGoethe University·Phase 4·NCT00199056·225 enrolled

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Completed· Incyte logo

Incyte·Phase 2·NCT02723994·171 enrolled

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02828358·78 enrolled

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·352 enrolled

SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06533748·128 enrolled

Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)

Recruiting·UUniversity of Chicago·Phase 1·NCT03571321·15 enrolled

Lymphoblastic Lymphoma5 trials

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00004228·393 enrolled

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01451515·23 enrolled

Show 2 more trials

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Terminated·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00275106·600 enrolled

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

B Acute Lymphoblastic Leukemia4 trials

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06124157·222 enrolled

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Recruiting·CChildren's Oncology Group·Phase 3·NCT03959085·5,951 enrolled

Show 1 more trial

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled

Acute Myeloid Leukemia3 trials

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1·NCT00004056·35 enrolled

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Completed·UUniversity Hospital Muenster·Phase 3·NCT00266136·3,500 enrolled

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02521493·280 enrolled

Bone Marrow Transplantation3 trials

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

Unknown status·MMedical Research Council·Phase 3·NCT00002658·2,000 enrolled

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00002665·50 enrolled

17 more indications

Leukemia3 trials

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002812·2,078 enrolled

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00002531

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00003671·59 enrolled

Myelodysplastic Syndrome2 trials

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·LLeukemia Research Fund·Phase 3·NCT00005823·2,000 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002517

Lymphoma2 trials

Combination Chemotherapy in Treating Children With Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002590·221 enrolled

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Unknown status·UUnited Kingdom Children's Cancer Study Group·Phase 3·NCT00003423·100 enrolled

T-cell acute lymphoblastic leukemia2 trials

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06390319·100 enrolled

Acute Promyelocytic Leukemia1 trial

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled

Myelodysplastic Syndromes1 trial

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·CChildren's Oncology Group·Phase 3·NCT00369317·205 enrolled

Chemotherapy1 trial

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Completed·CChildren's Oncology Group·Phase 3·NCT00002944·428 enrolled

Acute Leukemia1 trial

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Children1 trial

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

R/R AML1 trial

DEC-C and Thioguanine for R/R AML

Withdrawn·—·Phase 2·NCT06351306

Maintenance Therapy1 trial

Thiopurine EnhAnced Maintenance Therapy

Completed·KKjeld Schmiegelow·Phase 1/2·NCT02912676·30 enrolled

Myeloproliferative Disorder1 trial

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 3·NCT00003593·254 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled

T lymphoblastic leukemia/lymphoma1 trial

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Not yet recruiting·CChildren's Oncology Group·Preclinical·NCT07072585·1,708 enrolled

Adult T Acute Lymphoblastic Leukemia1 trial

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02112916·847 enrolled

Recurrent B Acute Lymphoblastic Leukemia1 trial

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02101853·669 enrolled

T Acute Lymphoblastic Leukemia1 trial

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00408005·1,895 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 18, 1966

THIOGUANINE

NDA NDA012429

Feb 11, 1977

THIOGUANINE

NDA NDA012429

Aug 24, 1978

THIOGUANINE

NDA NDA012429

Jan 1, 1982

THIOGUANINE

NDA NDA012429

Mar 13, 1984

THIOGUANINE

NDA NDA012429

Aug 6, 1985

THIOGUANINE

NDA NDA012429

Nov 20, 1985

THIOGUANINE

NDA NDA012429

Sep 22, 1986

THIOGUANINE

NDA NDA012429

Apr 9, 1987

THIOGUANINE

NDA NDA012429

Jul 18, 1988

THIOGUANINE

NDA NDA012429

Apr 5, 1990

THIOGUANINE

NDA NDA012429

Jul 15, 1991

THIOGUANINE

NDA NDA012429

Dec 12, 2001

THIOGUANINE

NDA NDA012429

Jul 3, 2002

THIOGUANINE

NDA NDA012429

Jun 30, 2003

THIOGUANINE

NDA NDA012429

Dec 19, 2003

THIOGUANINE

NDA NDA012429

Nov 15, 2004

THIOGUANINE

NDA NDA012429

May 23, 2018

THIOGUANINE

NDA NDA012429

Jul 9, 2024

THIOGUANINE

NDA NDA012429

Sources

References

[1]
ClinicalTrials.gov — 76 trial records for Thioguanine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tabloid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Thioguanine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Thioguanine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA012429). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Inosine-5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Akero Therapeutics

Tabloid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Acute Lymphoblastic Leukemia39 trials

Lymphoblastic Lymphoma5 trials

B Acute Lymphoblastic Leukemia4 trials

Acute Myeloid Leukemia3 trials

Bone Marrow Transplantation3 trials

Leukemia3 trials

Myelodysplastic Syndrome2 trials

Lymphoma2 trials

T-cell acute lymphoblastic leukemia2 trials

Acute Promyelocytic Leukemia1 trial

Myelodysplastic Syndromes1 trial

Chemotherapy1 trial

Acute Leukemia1 trial

Children1 trial

R/R AML1 trial

Maintenance Therapy1 trial

Myeloproliferative Disorder1 trial

Acute Leukemia of Ambiguous Lineage1 trial

T lymphoblastic leukemia/lymphoma1 trial

Adult T Acute Lymphoblastic Leukemia1 trial

Recurrent B Acute Lymphoblastic Leukemia1 trial

T Acute Lymphoblastic Leukemia1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News